Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended February 28, 1995, for National Medical Enterprises, Inc. (NME). Effective March 1, 1995, the company began operating as Tenet Healthcare Corporation following the acquisition of American Medical Holdings, Inc. (AMH). The filing reflects the company's transition from a diversified healthcare operator to a focused general hospital provider, marked by the divestiture of psychiatric, rehabilitation, and renal dialysis operations.
Key Financial Metrics
| Metric | Three Months Ended Feb 28, 1995 | Nine Months Ended Feb 28, 1995 | Nine Months Ended Feb 28, 1994 |
|---|---|---|---|
| Net Operating Revenues | $660.5 million | $1,962.1 million | $2,246.3 million |
| Operating Income | $88.7 million | $258.4 million | $272.8 million |
| Net Income (Continuing Ops) | $48.9 million | $159.1 million | $204.6 million |
| Net Income (Total) | $48.9 million | $159.1 million | $(431.3 million) |
| Diluted EPS (Continuing Ops) | $0.28 | $0.91 | $1.16 |
| Cash and Equivalents | $144.5 million | Balance Sheet Item | |
| Total Debt (Current + Long-term) | $738.3 million | Balance Sheet Item | |
| Working Capital | $391.9 million | Balance Sheet Item |
Note: Total Debt calculated as Current portion of long-term debt ($12.7M) + Short-term borrowings ($114.0M) + Long-term debt ($725.6M) = $852.3M. However, Note 8 indicates $449.9M of current debt was reclassified as long-term due to refinancing. The reported current liabilities total $624.9M and long-term debt $725.6M.
Material Changes vs. Prior Period
- Revenue Decline: Net operating revenues decreased 7.8% in the quarter and 12.7% in the nine-month period compared to the prior year. This is primarily due to the divestiture of Total Renal Care (August 1994), rehabilitation hospitals (January/March 1994), and long-term care facilities.
- Profitability Improvement: Despite lower revenues, operating income margins improved to 13.4% (quarter) and 13.2% (nine months) from 13.1% and 12.1% in the prior year, driven by cost control and the sale of lower-margin rehabilitation assets.
- Discontinued Operations: The prior year's net loss of $431.3 million was heavily impacted by discontinued psychiatric operations (loss of $696.0 million). The current period shows no discontinued operations loss, as these assets were largely disposed of or reserved.
- Liquidity Shift: Cash and cash equivalents decreased by $168.7 million to $144.5 million, primarily due to expenditures resolving legal proceedings related to the discontinued psychiatric business. Working capital improved from a deficit of $196.3 million (May 1994) to a surplus of $391.9 million (Feb 1995) following debt refinancing.
Guidance, Outlook, and Risks
Merger and Outlook
On March 1, 1995, NME acquired AMH for approximately $1.5 billion in cash and $489 million in stock. The company expects annual cost savings of approximately $60 million starting in fiscal 1996. Capital expenditures are projected at $400 million annually for the next three years, financed by operations and a new $2.3 billion credit facility.
Legal and Contingencies
- Psychiatric Litigation: The company faces ongoing litigation regarding its former psychiatric operations. A reserve of $68.7 million has been established for estimated legal costs and settlements, with $60.6 million expected to be paid within one year. Management notes that ultimate liability could exceed estimates.
- Hillhaven Dispute: NME filed a lawsuit against The Hillhaven Corporation alleging breach of fiduciary duty and dilution of NME's equity interest. NME owns approximately 27% of Hillhaven.
- Merger Litigation: Nine class-action lawsuits have been filed challenging the AMH merger, seeking rescission or damages. Management believes these claims are without merit.
Industry Risks
The company cites increased competition, payor pressure to shift services to outpatient settings, and rising allowances/discounts due to managed care growth as ongoing challenges to revenue stability.
Investor Verification Checklist
- Debt Refinancing Terms: Verify the specific covenants and interest rates of the new $2.3 billion credit facility and the $1.2 billion in new public debt issued to finance the AMH merger.
- Legal Reserve Adequacy: Monitor the $68.7 million reserve for psychiatric litigation to ensure it covers actual settlement costs and legal fees, given the uncertainty of ongoing lawsuits.
- Merger Integration: Assess the realization of the projected $60 million in annual cost savings from the AMH merger in subsequent quarters.
- Hillhaven Equity Value: Track the outcome of the litigation with Hillhaven and the potential dilution of NME's 27% stake, which impacts the valuation of this significant investment.
- Pro Forma Accuracy: Compare actual post-merger results against the unaudited pro forma financial data provided in Note 7 to evaluate the accuracy of the merger's financial impact.